Conclusion
The histogenesis and immunohistochemical profile of HCO have yet to be
determined. AFP staining has been shown routinely positive but still
with several exceptions. SALL4 may be regarded as a good indicator of
HCO despite its low positive rate(22). Both AFP and CA125, rather than
HE4, can be employed as prognostic biomarkers and may be used to track
therapy response and screen for recurrence. Treatment approaches are not
unified, but a cytoreductive surgery followed by a platinum and
taxane-based chemotherapy has shown similar results to other ovarian
carcinomas. The second-line therapy after platinum resistance requires
further exploration.